Biologicals have dominated the therapeutic scenery in inflammatory bowel diseases (IBDs),
namely ulcerative colitis (UC) and Crohn's disease (CD), for the past 20 years. The …

Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract that might lead
to progressive bowel damage and disability. The exact cause of Crohn's disease is …

Mucosal healing on endoscopy has emerged as a key prognostic parameter in the
management of patients with IBD (Crohn's disease, ulcerative colitis/UC) and can predict …

Upadacitinib is a selective Janus kinase (JAK) inhibitor which is approved by the US Food
and Drug Administration, the European Medicines Agency, as well as other agencies …

Introduction Most guidelines for IBD still recommend step-by-step therapy with initially
classic drugs such aminosalicylates (in ulcerative colitis) or steroids but avoid prioritizing …

Simple Summary Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory
bowel diseases that affect the gut and extraintestinal organs. Preliminary evidence has …

Janus kinase inhibitors (JAKi) are oral small molecules used in the treatment of a broad
spectrum of autoimmune and myeloproliferative diseases. JAKi exhibit significant intra-and …

Inflammatory Bowel Diseases had their first peak in incidence in countries in North America,
Europe, and Oceania and are currently experiencing a new acceleration in incidence …

Background A previous controlled trial of autologous haematopoietic stem-cell
transplantation (HSCT) in patients with refractory Crohn's disease did not meet its primary …

Inflammatory bowel diseases (IBDs) including Crohn's disease (CD), ulcerative colitis (UC)
and inflammatory bowel disease unclassified (IBD-U) are chronic inflammatory disorders …